NeuBase Therapeutics, Inc.
Hedge Funds Holdings
Last updated:
NeuBase Therapeutics, Inc.‘s stocks are currently a part of 20 hedge funds’ portfolios, which represents 10.71% of the total amount of its stocks outstanding. This makes up a total of 3.53M shares of NeuBase Therapeutics, Inc.. Compared to the previous quarter, the number fell by -65.12% or -6.60M shares fewer. As for the holding position changes, 20% (4) of current hedge fund investors increased the number of shares held, 20% (4) of current holders sold a part of the shares held, and 10% (2) closed the holdings completely. 4 hedge funds are new holders of NeuBase Therapeutics, Inc. stock in Q1 2023, it is 20% of total holders.
Hedge funds holding NeuBase Therapeutics (Q3 2019 – Q1 2023)
| Q3 2019 | 16 |
|---|---|
| Q4 2019 | 22 |
| Q1 2020 | 25 |
| Q2 2020 | 47 |
| Q3 2020 | 50 |
| Q4 2020 | 53 |
| Q1 2021 | 56 |
| Q2 2021 | 56 |
| Q3 2021 | 46 |
| Q4 2021 | 44 |
| Q1 2022 | 43 |
| Q2 2022 | 36 |
| Q3 2022 | 36 |
| Q4 2022 | 32 |
| Q1 2023 | 20 |
Hedge funds changes in NeuBase Therapeutics positions (Q3 2019 – Q1 2023)
| Q3 2019 | 16 | 0 | 0 | 0 | 0 |
|---|---|---|---|---|---|
| Q4 2019 | 10 | 5 | 2 | 4 | 1 |
| Q1 2020 | 10 | 5 | 3 | 6 | 1 |
| Q2 2020 | 28 | 12 | 2 | 6 | -1 |
| Q3 2020 | 13 | 13 | 15 | 10 | -1 |
| Q4 2020 | 10 | 20 | 12 | 7 | 4 |
| Q1 2021 | 11 | 19 | 15 | 8 | 3 |
| Q2 2021 | 15 | 17 | 17 | 15 | -8 |
| Q3 2021 | 1 | 12 | 18 | 11 | 4 |
| Q4 2021 | 6 | 10 | 11 | 8 | 9 |
| Q1 2022 | 7 | 8 | 12 | 8 | 8 |
| Q2 2022 | 4 | 6 | 7 | 11 | 8 |
| Q3 2022 | 5 | 4 | 9 | 5 | 13 |
| Q4 2022 | 7 | 5 | 7 | 11 | 2 |
| Q1 2023 | 4 | 4 | 4 | 2 | 6 |
Hedge funds changes in NeuBase Therapeutics stock options (Q3 2019 – Q1 2023)
| Q3 2019 | 0 | 0 |
|---|---|---|
| Q4 2019 | 0 | 0 |
| Q1 2020 | 0 | 0 |
| Q2 2020 | 0 | 0 |
| Q3 2020 | 0 | 0 |
| Q4 2020 | 17,000 | 0 |
| Q1 2021 | 145,000 | 1,000 |
| Q2 2021 | 508,000 | 187,000 |
| Q3 2021 | 147,000 | 119,000 |
| Q4 2021 | 12,000 | 51,000 |
| Q1 2022 | 56,000 | 15,000 |
| Q2 2022 | 14,000 | 0 |
| Q3 2022 | 0 | 0 |
| Q4 2022 | 0 | 0 |
| Q1 2023 | 0 | 0 |